BiotechTube

Bomedemstat + Atezolizumab

Phase 1/2Terminated
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Extensive Stage Lung Small Cell Carcinoma

Conditions

Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma

Trial Timeline

Apr 11, 2022 → Apr 5, 2024

NCT ID
NCT05191797

About Bomedemstat + Atezolizumab

Bomedemstat + Atezolizumab is a phase 1/2 stage product being developed by Merck for Extensive Stage Lung Small Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05191797. Target conditions include Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05191797Phase 1/2Terminated

Competing Products

20 competing products in Extensive Stage Lung Small Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
ALPS12 + obinutuzumabChugai PharmaceuticalPhase 1
33
Ifinatamab Deruxtecan (I-DXd)Daiichi SankyoPhase 2
52
Gocatamig + I-DXd + Atezolizumab + Carboplatin + Etoposide + Rescue MedicationsDaiichi SankyoPhase 1/2
41
Ifinatamab deruxtecan + Atezolizumab + CarboplatinDaiichi SankyoPhase 1/2
41
Valemetostat + AtezolizumabDaiichi SankyoPhase 1
33
LY2510924 + Carboplatin + EtoposideEli LillyPhase 2
52
SHR-1316 + Carboplatin + Etoposide + PlaceboJiangsu Hengrui MedicinePhase 3
77
Epirubicin plus SHR1210Jiangsu Hengrui MedicinePhase 2
52
Durvalumab plus chemotherapyAstraZenecaPhase 3
77
Durvalumab + Tremelimumab + Olaparib Pill + TremelimumabAstraZenecaPhase 1
33
Neoantigen DNA vaccine + DurvalumabAstraZenecaPhase 2
52
Etoposide with Carboplatin or Cisplatin + DurvalumabAstraZenecaPhase 2
52
Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + CarboplatinAstraZenecaPhase 1
33
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparibAstraZenecaPhase 2
52
Durvalumab + Cisplatin + Etoposide + CarboplatinAstraZenecaPhase 3
77
Durvalumab + Cisplatin + Carboplatin + EtoposideAstraZenecaPhase 3
77
Cisplatin + Carboplatin + Etoposide + Durvalumab + CeralasertibAstraZenecaPhase 2
52
Carboplatin + Cisplatin + Durvalumab + EtoposideAstraZenecaPhase 2
52
Carboplatin + Durvalumab + Etoposide + OlaparibAstraZenecaPhase 1/2
41
Durvalumab + Tremelimumab + Carboplatin + Cisplatin + EtoposideAstraZenecaPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85